Figure 1 Refractory Patients’ Serum IgM Levels After Treatment with Mavorixafor + Ibrutinib vs. Ibrutinib Monotherapy With or Without CXCR4…
Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8…
Results to be presented for the first time show mosunetuzumab induces high and durable complete response rates in people with…
NEWS RELEASE – REGULATED INFORMATION 10 December 2021, 23:55 CET MDxHealth Shareholder Transparency Declaration IRVINE, CA, and HERSTAL, BELGIUM –…
EDGEWATER, N.J., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Joseph Frontiere, CEO of Quad M Solutions, Inc. said “Quad M Solutions…
BEDFORD, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early…
ACTON, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs…
Boards have made small advances in diversity; less time is spent on strategic planningLINCOLN, Neb., Dec. 10, 2021 (GLOBE NEWSWIRE)…
Monthly information regarding the total number of voting rights and total number of shares of the Company as of November…
MENLO PARK, Calif. and BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company…